Destiny Pharma
plc
("Destiny Pharma" or "the Company")
XF-73 treatment of MRSA burn
wound infection prevents bacterial invasion of the
bloodstream
Data to be presented at the
Infection Prevention Society conference
Brighton, United Kingdom - 5
August 2024 - Destiny Pharma (AIM: DEST), a clinical stage
biotechnology company focused on the development and
commercialisation of novel medicines to prevent and cure life
threatening infections, today announced that new data on its lead
drug, Exeporfinium chloride(XF-73)*, has been accepted for
presentation at the Infection Prevention Society conference on the
23-25 September 2024 in Birmingham, UK.
The title of the presentation is,
'Inhibition of MRSA
Infection by Exeporfinium Chloride (XF-73) in an In Vivo Burn Wound
Model.'
The data was generated from a study in which
XF-73 was applied directly onto a methicillin resistant
Staphylococcus aureus
(MRSA) infected burn wound with subsequent monitoring of the spread
of the MRSA into the bloodstream. When bacteria such as MRSA enter
the bloodstream it can cause a life-threatening infection condition
called sepsis which has a high mortality rate. The study also
included a control placebo treatment arm.
The headline results which will be presented at
the Infection Prevention Society conference include:
·
Following a single topical application of 25, 50 or 100 µg of
XF-73, MRSA infection within the burn wound tissue was
significantly reduced by up to 99.99% compared to the placebo
treatment, (p<0.05)
· The
appearance of MRSA within the bloodstream (i.e. sepsis) was
measured by monitoring the number of MRSA bacteria within the
spleen and results from the three XF-73 dosed groups (each n=8)
showed a significant 99.9% reduction of MRSA reaching the
bloodstream, (p<0.05)
· In
one of the XF-73 treatment groups, (50 µg), it was observed that no
MRSA had reached the bloodstream resulting in the complete
prevention of sepsis
Globally, it is estimated that there are
approximately 9 million burn cases per year1. Burn
injuries contribute to >250,000 fatalities2 with infections
identified as the cause of 61% of post-burn deaths3. Recent reports
show the incidence of sepsis in burn patients ranges from 8% to 42%
with related mortality from 28-65%4. Staphylococcus aureus, (including
MRSA), is a common cause of post-burn infection, with reports that
patients with burns had a prevalence of S. aureus of 57.8%5.
Dr Bill Love,
Chief Scientific Officer Destiny Pharma, said:
"These results from an in vivo burn wound
infection model provide clear evidence that XF-73 can significantly
reduce the risk, or even eliminate MRSA from reaching the
bloodstream and causing sepsis. It is seen as a significant result
for the continued development of our XF-73 dermal
product."
* XF-73, is a di-cationic porphyrin derivative
with known rapid and potent bactericidal properties (MICs
0.25-4mg/L for all Gram positive bacteria tested to date) with a
low propensity for engendering bacterial resistance. XF-73 has
recently completed Phase 2 clinical study as an intranasal gel for
decolonization of S.
aureus, (including MRSA), to prevent post-surgical
infections.
References:
1. Greenhalgh DG. Management of Burns. N
Engl J Med. 2019 Jun 13;380(24):2349-2359. doi:
10.1056/NEJMra1807442. PMID: 31189038.
2. Moeini A, Pedram P,
Makvandi P, Malinconico M, Gomez d'Ayala G. Wound healing and
antimicrobial effect of active secondary metabolites in
chitosan-based wound dressings: A review. Carbohydr Polym. 2020 Apr
1;233:115839. doi: 10.1016/j.carbpol.2020.115839. Epub 2020 Jan 13.
PMID: 32059889.
3. Gomez R,
Murray CK, Hospenthal DR, Cancio LC, Renz EM, Holcomb JB, Wade CE,
Wolf SE. Causes of mortality by autopsy findings of
combat casualties and civilian patients admitted to a burn unit. J
Am Coll Surg. 2009 Mar;208(3):348-54. doi:
10.1016/j.jamcollsurg.2008.11.012. Epub 2009 Jan 21. PMID:
19317995.
4. Cabral L,
Afreixo V, Santos F, Almeida L, Paiva JA.
Procalcitonin for the early diagnosis of sepsis in burn
patients: A retrospective study. Burns. 2017 Nov;43(7):1427-1434.
doi: 10.1016/j.burns.2017.03.026. Epub 2017 Apr 25. PMID:
28454850.
5. Alebachew T, Yismaw G,
Derabe A, Sisay Z. Staphylococcus aureus burn wound infection among
patients attending yekatit 12 hospital burn unit, addis ababa,
ethiopia. Ethiop J Health Sci. 2012 Nov;22(3):209-13. PMID:
23209356; PMCID: PMC3511900.
For further information, please
contact:
Destiny Pharma plc
Chris Tovey, CEO
Shaun Claydon, CFO
+44 (0)1273 704 440
pressoffice@destinypharma.com
FTI Consulting
Ben Atwell / Simon Conway
+44 (0) 203 727 1000
destinypharma@fticonsulting.com
About Destiny
Pharma
Destiny Pharma is an innovative, clinical-stage
biotechnology company focused on the development and
commercialisation of novel medicines that can prevent
life-threatening infections. The Company's drug development
pipeline includes two late-stage assets XF-73 Nasal gel, a
proprietary drug targeting the prevention of post-surgical
staphylococcal hospital infections including MRSA and NTCD-M3, a
microbiome-based biotherapeutic for the prevention of C. difficile
infection (CDI) recurrence which is the leading cause of hospital
acquired infection in the US.
For further information on the company, please visit
www.destinypharma.com.